ArticleJournal of surgical case reports2026
Multiple breast tumors coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare case report.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concurrent presentation of multiple breast carcinomas with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is exceptionally rare in clinical practice. This report presents the case of a 77-year-old woman with two distinct right breast carcinomas. The patient underwent neoadjuvant carboplatin/paclitaxel chemotherapy with pembrolizumab, achieving partial radiologic response. Following neoadjuvant therapy, the patient underwent right breast mastectomy with sentinel lymph node biopsy, which was positive, prompting subsequent axillary lymph node dissection. Post-mastectomy pathology revealed residual ductal carcinoma with marked treatment effect, persistent lobular carcinoma, and multifocal CLL/SLL infiltration in breast tissue with metastasis to axillary lymph nodes. The final staging was ympT1c N1a and the patient recommended for adjuvant pembrolizumab plus capecitabine with radiotherapy for breast carcinoma and surveillance with positron emission tomography-computed tomography for CLL. The outcome underscores the importance of meticulous histopathological and immunohistochemical evaluation in distinguishing concurrent malignancies from metastatic or reactive lymphoid infiltrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.